Immunic (IMUX) revenue and earnings history
Immunic's annual figures for 14 fiscal years, as filed with the SEC.
Revenue and net income, 14 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | — | −$103M | −$97.2M | −$85.8M | $161K | −$86M | $8.86M | — | — | $15.5M | — | 10-K |
| 2024ended Dec 31, 2024 | — |
The latest quarter, insider trades and fund moves: Immunic (IMUX) on OQRO.
Common questions
Has Immunic been profitable?
It reported a net loss in 14 of the years shown (2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$6.7M in fiscal 2012.
What was Immunic's free cash flow in fiscal 2025?
−$86M: operating cash flow of −$85.8M minus capital expenditure of $161K. OQRO calculates free cash flow this way from the two filed lines.
Does Immunic buy back shares or pay dividends?
None of the 14 annual reports shown tags a share buyback or a dividend payment in the standard US taxonomy.
Why is earnings per share not in this table?
Where these figures come from
The SEC’s companyfacts data: every figure Immunic tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
